Alveolar macrophage lipid burden correlates with clinical improvement in patients with Pulmonary Alveolar Proteinosis
bioRxiv, ISSN: 2692-8205
2022
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Pulmonary alveolar proteinosis (PAP) is a life-threatening rare lung syndrome characterized by the accumulation of surfactant and lipid-loaded macrophages within the alveoli for which there is no cure and no approved therapies. The clinical diagnosis of PAP, often made by invasive lung biopsies and/or cytology of bronchoalveolar lavage fluid does not identify the underlying cause of disease. In addition, no biomarkers exist to inform prognosis or therapeutic options in PAP. We now report on the use of comprehensive mass spectrometry to profile and define the lipid signature of alveolar macrophages obtained from PAP patients. In addition, we quantify how these macrophage-associated lipids change during clinical treatment. Our studies demonstrate that clinical improvement in treated PAP patients is associated with a decrease in total lipid content, indicating that levels of these macrophage-associated lipids correlate with the severity of the disease.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know